Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31691849 | 1.00 | ALOX5 (0.43) | ALOX5TYK2JAK1OPRM1DRD2 | |
| SCHEMBL23126514 | 0.87 | SLC6A2 (0.39) | ALOX5OPRM1DRD2DRD3CYP2D6 | |
| SCHEMBL24447308 | 0.81 | GRIN1 (0.42) | ALOX5OPRM1CYP2D6HRH3SLC6A2 | |
| SCHEMBL29546485 | 0.79 | TYK2 (0.41) | ALOX5TYK2JAK1 | |
| SCHEMBL21359003 | 0.78 | TYK2 (0.35) | ALOX5TYK2JAK1 | |
| SCHEMBL26685461 | 0.78 | ALOX5 (0.38) | ALOX5TYK2JAK1OPRM1CYP2D6 | |
| SCHEMBL15291844 | 0.77 | HRH3 (0.36) | ALOX5OPRM1DRD2DRD3CYP2D6 | |
| SCHEMBL21330129 | 0.76 | TYK2 (0.42) | ALOX5TYK2JAK1 | |
| SCHEMBL21329679 | 0.76 | ALOX5 (0.44) | ALOX5TYK2JAK1 | |
| SCHEMBL21329681 | 0.76 | ALOX5 (0.44) | ALOX5TYK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2019178079-A9 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019178079-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | ALOX5 4798/4885TYK2 36/4885JAK1 41/4885 |
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | ALOX5 4798/4885TYK2 36/4885JAK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.